- Home
- / Ra Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Ra Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Revenue
$3 M
FY, 2019
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
|---|---|---|---|---|
| Revenue | 4.9M | 2.5M | 3.0M | |
| General and administrative expense | 5.0M | 9.8M | 14.4M | 27.3M |
| Operating expense total | 33.0M | 55.0M | 68.9M | 110.0M |
| EBIT | (28.0M) | (55.0M) | (66.4M) | (107.0M) |
| EBIT margin, % | -568.7% | -2655.5% | -3566.0% | |
| Interest income | 109.0K | 645.0K | 1.5M | 4.3M |
| Interest expense | 858.0K | 571.0K | 1.4M | 4.3M |
| Pre tax profit | (28.9M) | (54.5M) | (65.0M) | (102.7M) |
| Income tax expense | (18.0K) | (19.0K) | (19.0K) | |
| Net Income | (28.9M) | (54.4M) | (64.9M) | (102.7M) |